PMID- 34151608
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 27
DP  - 2021 Jan-Dec
TI  - National Trends for Peripheral Artery Disease and End Stage Renal Disease From 
      the National Inpatient Sample Database.
PG  - 10760296211025625
LID - 10.1177/10760296211025625 [doi]
LID - 10760296211025625
AB  - Peripheral artery disease (PAD), and subsequent chronic limb-threatening ischemia 
      (CLTI), are frequently encountered among patients with end-stage renal disease 
      (ESRD). Their coexistence is less favorable in comparison to patients with ESRD 
      alone. We sought to investigate trends, comorbidities, determinants for cost, and 
      prognostic outcomes in patients with concomitant ESRD and PAD. A retrospective 
      analysis was performed using data from the National Inpatient Sample database 
      from the years 2005-2014. ICD-9 codes were used to identify patients with 
      diagnoses of PAD, CLTI, and ESRD. Pearson's Chi-square, T-test, ANOVA, and 
      multivariate binary logistic regression were used in this analysis. 7,214,843 
      patients with ESRD were identified. Of these, 123,499 patients were diagnosed 
      with PAD and 102,447 with CLTI. Compared to ESRD alone, mortality rates increased 
      with PAD and CLTI (5.7% vs. 13.9% vs. 15.9%, P < 0.001). Length of stay in days 
      (7.3 vs. 10.2 vs. 11.1, P < 0.001) and in-hospital costs (59,872 vs. 85,866 vs. 
      89,016, P < 0.001) were higher with PAD and CLTI, respectively. CLTI demonstrated 
      the highest independent predictor of mortality [OR = 6.93 (6.43-7.46), P < 
      0.001]. A decreasing trend in the rate of PAD (2005: 1.9% vs. 2014: 1.4%, P < 
      0.001) and CLTI (2005: 1.6% vs. 2014: 1.1%, P < 0.001) was noted. The presence of 
      coexisting PAD, and furthermore CLTI, in patients with ESRD significantly raised 
      in-hospital mortality, cost, and length of stay. A negative trend in rates of PAD 
      and CLTI were observed. Proactive identification of this high-risk population may 
      lead to accurate diagnosis and tailored therapeutic strategies.
FAU - De Stefano, Frank
AU  - De Stefano F
AUID- ORCID: 0000-0003-1709-0148
AD  - Kansas City University of Medicine and Biosciences, Kansas City, MO, USA.
FAU - Rios, Luis H Paz
AU  - Rios LHP
AUID- ORCID: 0000-0001-7024-8990
AD  - Northshore University Health Systems Cardiovascular Institute, Evanston, IL, USA.
FAU - Fiani, Brian
AU  - Fiani B
AD  - Department of Neurosurgery, Desert Regional Medical Center, Palm Springs, CA, 
      USA.
FAU - Fareed, Jawed
AU  - Fareed J
AUID- ORCID: 0000-0003-3465-2499
AD  - Department of Pathology, Loyola University, Chicago, IL, USA.
FAU - Tafur, Alfonso
AU  - Tafur A
AD  - Northshore University Health Systems Cardiovascular Institute, Evanston, IL, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Inpatients
MH  - Kidney Failure, Chronic/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Peripheral Arterial Disease/*epidemiology
MH  - Prognosis
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC8221664
OTO - NOTNLM
OT  - atherosclerosis
OT  - peripheral arterial disease
OT  - renal disease
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/06/22 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/06/21
CRDT- 2021/06/21 08:42
PHST- 2021/06/21 08:42 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/06/21 00:00 [pmc-release]
AID - 10.1177_10760296211025625 [pii]
AID - 10.1177/10760296211025625 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211025625. doi: 
      10.1177/10760296211025625.